Key facts
- Eupnoos’s last known valuation is $2.6M (Mar 2025).
- It has raised $490K; the latest was Later Stage VC ($490K) in Mar 2025.
- Notable investors include Innovate UK, MassChallenge, MedTech Innovator, SFC Capital, Kunsen — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Eupnoos
- ·The full record, as it builds
Funding rounds
No funding rounds for Eupnoos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eupnoos
Developer of a smartphone-based application designed to provide digital therapeutic services. The company uses the microphone and camera to screen, measure, stratify, and stage progression and offers clinical lung function tests and symptom-guided assessments, enabling people to understand the health of their lungs and get access to general health and wellness monitoring and clinical decision-making from health professionals.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 4
- Website
- eupnoos.com/
- Ownership
- Privately Held (backing)
Eupnoos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eupnoos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eupnoos in its N-PORT filings yet. We sweep new filings monthly.